Spotlight Innovation Licenses Additional Anti-Zika Virus Compounds
URBANDALE, Iowa, Feb. 15, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that it has entered into a second license agreement with the Florida State University Research Foundation (FSURF) for the development and commercialization of additional anti-Zika virus compounds. As with the initial license agreement, this agreement grants to Spotlight Innovation exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus infection.
John Krohn, Spotlight Innovation's President and Chief Operating Officer, said, "This new Zika-focused license agreement, which complements our first agreement, affirms our ongoing commitment to develop pioneering treatments for emerging diseases such as Zika virus infection."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Spotlight Innovation Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-licenses-additional-anti-zika-virus-compounds-300407669.html
SOURCE Spotlight Innovation Inc.
Released February 15, 2017